ELUTIA INC. 8K

Elutia Inc. agreed to sell its SimpliDerm business to Cellution Biologics Inc. for up to $11 million to strengthen its balance sheet and focus resources on its NXT-41x pipeline product.

Elutia Inc. announced that it has signed a definitive agreement to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million, consisting of $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 months, with closing expected in the second half of 2026; the divestiture completes Elutia’s strategic process for SimpliDerm and is intended to strengthen its balance sheet with non-dilutive capital and sharpen its strategic focus on advancing and commercializing its NXT-41x antibiotic-eluting biomatrix platform, targeted for U.S. launch in 2027 in the plastic and reconstructive surgery market.

Filing Facts

CIK

1708527

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-085061

Alert Tier

7